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Merkel Cell Carcinoma is an aggressive human skin cancer
induced by Merkel Cell Polyomavirus (MCPyV). MCPyV
is commonly found in human, but the oncogenic transfor-
mation takes place during immunosuppression. Two
mutation events allow the clonal integration of the viral
genome into the host genome and translation of the two
viral genes large T (LTA) and small T antigen (STA).
Standard treatment with chemotherapy shows poor clinical
outcome instead immunotherapy offers new potential
treatment strategies. The use of PD-1 checkpoint inhibi-
tors has shown promising results (>50% response rates,
RECIST). However, not all patients are able to mount an
immune response. Instead adoptive transfer of MCPyV-
reactive T cells is an attractive strategy for this cohort.
We have previously identified T cell epitopes from the
MCPyV-derived proteins LTA, STA and VP1. Here we aim
to expand the knowledge about T cell epitopes by
including a broader range of HLA restrictions. We
analyzed 31 patients’ peripheral blood mononuclear cells
through enrichment of low frequency clones, followed by
revealing of T cell reactivity using combinatorial color-
encoded peptide-MHC multimers. 28 T cell responses
against 18 MCPyV-derived peptides were detected. Addi-
tional testing has confirmed functional T cell reactivity
against one of these epitopes. We analyzed 3 patients’
tumor infiltrating lymphocytes by direct ex-vivo detection
of T cell reactivity using combinatorial color-encoded
peptide-MHC multimers. 5 T cell responses against 5
peptides were detected.
The functional T cell response towards detected epitopes is
under investigation in order to characterize them as
potential T cell targets in a new therapy.
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Human cancers frequently display defects in their antigen
(Ag) processing and presentation pathway that allow for
immune evasion, and therefore constitute a significant
challenge for T cell-based immunotherapy. T cell epitopes
associated with impaired peptide processing (TEIPP)
constitute a novel category of immunogenic Ags that are
selectively presented on transporter associated with Ag
processing–deficient cells. The TEIPP neoepitopes are CD8
T cell targets, derived from non-mutated self-proteins that
might be exploited to prevent immune escape. Further-
more, we have previously demonstrated that alteration of
cancer epitopes at position 3 to a proline residue in H-2Db-
binding peptides strongly increases MHC/peptide complex
stability and immunogenicity. We have determined the
crystal structure of H-2Db in complex with the first
identified TEIPP Ag (MCLRMTAVM) derived from the
Trh4 protein, demonstrating that the peptide induce a
non-canonical conformer of His155, known to be impor-
tant for TCR recognition. Also, we have determined the
crystal structure of H-2Db in complex with the p3P-
modified Thr4 variant since in vivo and in vitro results
demonstrate that vaccination with Thr4-p3P results in
significantly enhanced recognition by anti-tumour CTLs.
Comparison of structures and functional results provide
interesting insights to this epitope.
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